Enterobacter species are increasingly a cause of nosocomial meningitis among neurosurgery patients, but risk factors for these infections are not well defined. A review of all adult patients hospitalized at the University of California-Los Angeles (UCLA) Medical Center during an 8-year period identified 15 postneurosurgical cases of Enterobacter meningitis (EM). Cure was achieved in 14 cases (93%), and efficacy was similar for carbapenem-and cephalosporin-based treatment. A matched case-control study comparing 26 controls with 13 case patients hospitalized exclusively at the UCLA Medical Center found that external cerebrospinal fluid (CSF) drainage devices (odds ratio [OR], 21.8; ), isolation of Enterobacter species from a non-CSF P p .001 culture (OR, 24.6; ), and prolonged administration of antimicrobial drugs before the diagnosis of P p .002 meningitis that were inactive in vitro against Enterobacter species (OR, 13.3; ) were independent risk P p .008 factors for EM. Despite favorable treatment outcomes, EM is a serious infection associated with Enterobacter species colonization or infection at other surgical sites, with selective antimicrobial pressure, and with invasive CNS devices.
1940s [8, 9] . More recently, Wolff et al. [7] described the association between Enterobacter species and postneurosurgical infection, but risk factors for Enterobacter meningitis (EM) were incompletely characterized. In this report, we describe the risk factors and treatment outcomes for EM during an 8-year period for patients treated at a tertiary care medical center with a large neurosurgical population.
PATIENTS AND METHODS
Case definition. We reviewed microbiological and laboratory records for the period from January 1992 through December 1999 to identify patients treated at the University of California-Los Angeles (UCLA) Medical Center, a 500-bed tertiary care teaching hospital, who were у18 years old and who had CSF cultures positive for Enterobacter species. A case of EM was defined on the basis of isolation of Enterobacter organisms from a CSF culture, a diagnosis of meningitis by the treating physician, and у1 of the following laboratory values: CSF WBC count of 110 cells/mm 3 , CSF protein level of 145 g/dL, and CSF glucose level of р50% of the serum glucose level. Positive cultures of CSF specimens obtained from patients whose illness did not meet the above criteria were considered to have been contaminated, and data for such patients were excluded from additional analysis. EM was considered to have been acquired at the UCLA Medical Center if meningitis developed у48 h after admission or if meningitis was present or incubating when the patient was admitted to this hospital during the 30 days before study entry. All other cases were defined as community acquired. This research was approved by the UCLA Institutional Review Board.
Descriptive epidemiology. Demographic, clinical, and treatment characteristics were abstracted from the medical records of each case patient. Severity of illness was assessed at the time of admission and the initial positive CSF culture on the basis of the Glasgow Coma Scale (GCS) score and, if the patient underwent a neurological procedure, the American Society of Anesthesia (ASA) score [10, 11] . Antimicrobial exposure was assessed for the 30-day period before the initial CSF Enterobacter isolate was recovered and was defined as "prophylactic," if a single dose of cefazolin or vancomycin was administered before surgery; as "empirical," if administered for 24-72 h; and as "therapeutic," if administered for 172 h or for the treatment of a documented or presumed Enterobacter infection.
Microbiological data, including the type of Enterobacter species isolated, the site of isolation, and the antimicrobial susceptibility profiles, were recorded. Non-CSF Enterobacter isolates were defined as "prior isolates" if recovered from culture during the 30 days before or as "concurrent isolates" if recovered on the same day as the first positive CSF culture result. Antimicrobial susceptibility testing was performed using the broth microdilution method with microdilution trays prepared in-house.
Data for the antimicrobial treatment of EM was recorded and included drug names, doses administered, routes of administration, and duration of therapy. Antimicrobial drugs were classified as active or inactive against Enterobacter species meningitis on the basis of in vitro susceptibility test results and CSF penetration. Aminoglycosides were classified as inactive if administered intravenously and as active if administered intrathecally. The predominant regimen was defined as the antimicrobial agent or agents administered on at least two-thirds of EM treatment days. Combination therapy for EM was defined as administration of у2 antimicrobial drugs that were active in vitro and in vivo against the strain.
Outcome measurements included duration of antimicrobial treatment, interval to sterilization of CSF, duration of hospitalization, disposition and Glasgow Coma Scale (GCS) score at discharge, and mortality. Cure was defined as complete resolution of signs and symptoms of meningitis and, if performed, no growth on subsequent CSF cultures. Treatment failure was defined as persistence of signs and symptoms of meningitis, persistence of unsterile CSF cultures, or death during treatment, regardless of cause.
Risk factor analysis. To determine risk factors associated with EM, we restricted analysis to cases of EM acquired at the UCLA Medical Center. For each patient, we randomly selected 2 controls from among all neurosurgical service patients hospitalized on the day that the case patient first received a diagnosis of EM (i.e., the referent date). Controls had to be у18 years of age and had to have been hospitalized at the UCLA Medical Center for a period that was at least as long as that of the case patient before they received a diagnosis of EM. Demographic, clinical, and treatment characteristics were assessed and included the following: neurological diagnosis, severity of illness, comorbidities, select laboratory findings, neurosurgical procedures performed, type of invasive device used during neurosurgery, and antimicrobial exposure history. A potential exposure had to occur у24 h before the referent date to be classified as present.
PFGE. Enterobacter isolates recovered from patients with EM were genotyped by PFGE with use of SpeI-restricted DNA isolates and were separated by a CHEF Mapper XA apparatus (Bio-Rad). Isolates that differed by у4 bands during visual inspection were considered to be unrelated [12] .
Statistical analysis. Data were collected and analyzed using Epi Info software, version 6.04b (Centers for Disease Control and Prevention), and SPSS Professional Statistics, version 10.0 (SPSS). Proportions were compared using the uncorrected x 2 test or Fisher's exact test. ORs and 95% CIs were calculated. Continuous variables were compared using Student's t test or the Mann-Whitney U test. Conditional logistic regression analysis was used to identify independent risk factors for EM; data for all significant variables identified by univariate analysis were entered in the model. P values were 2-tailed, and a value of !.05 was considered to be statistically significant.
RESULTS
Descriptive epidemiology. During the 8-year period of the study, 17 patients had Enterobacter species isolated from у1 CSF culture performed at the UCLA Medical Center (range, 1-5 patients per year). No patient had recurrent EM. Enterobacter species were more likely to be isolated from CSF cultures performed during the spring or summer than during other seasons (spring-summer vs. fall-winter, 13 of 17 isolates vs. 4 of 17 isolates, respectively;
). Enterobacter species were P p .01 the most common gram-negative CSF isolates recovered, representing 41.5% of gram-negative isolates and 2.4% of all CSF isolates. Of the 17 CSF isolates recovered, 15 met the case definition and 2 were contaminants. Thirteen cases of EM were acquired at the UCLA Medical Center, and the remaining 2 were acquired at other hospitals. All 15 cases occurred among patients who received neurosurgical service. The annual incidence of EM among patients who received neurosurgical service was 0.74-3.2 cases per 1000 neurosurgical service discharges.
Of the 15 patients with EM, 10 were men, and patients were 19-72 years old (table 1). The most common diagnoses at hospital admission included malignant brain tumor (6 patients [80%]) and subarachnoid hemorrhage (3 patients [20%]); 12 patients (80%) did not have any underlying comorbid medical conditions. Fourteen patients (93%) underwent у1 neurosurgical operation. Eleven patients (73%) had external CSF drainage catheters, including 6 ventriculostomies (40%) and 5 lumbar drains (33%). Seven patients (47%) required mechanical ventilation (median duration of therapy, 2 weeks). Ten patients (67%) underwent reoperation, most often for the treatment of postsurgical complications. Among the 13 cases acquired at the UCLA Medical Center, onset of EM occurred at a median interval of 8 days after the initial surgery and at a median interval of 1 day before the second surgery.
Before the diagnosis of EM, 14 patients (93%), including 9 (82%) of 11 patients with an external CSF drain, received antimicrobial drugs, most commonly cefazolin (10 patients [67%]) and vancomycin (4 patients [27%]), for a median duration of 4 days (range, 1-19 days). Nine patients (60%) received dexamethasone (median duration of therapy, 5 days) for prophylaxis for or treatment of elevated intracranial pressure.
Nine patients (60%) had prior ( ) or concurrent n p 2 ( )Enterobacter strains of the same species and with the n p 7 same susceptibility profile as those isolated from non-CSF sites. The 2 patients with prior isolates had respiratory colonization. Five of 7 concurrent non-CSF isolates were associated with infection (bacteremia in 2 patients and pneumonia, wound infection, and urinary tract infection in 1 patient each), and 2 were associated with colonization (at the enterostomy site and in sputum).
Clinical and laboratory characteristics of EM. On the day that EM was diagnosed, 9 patients (60%) had fever and 7 (47%) had a peripheral leukocytosis, with 1 cells/mm 3 (table   3 11.0 ϫ 10 2). CSF abnormalities included elevated WBC counts (median, 171 cells/mm 3 , with 67% polymorphonuclear leukocytes) in 14 patients (93%) and elevated CSF protein levels (median, 173 mg/dL) in 12 patients (80%). Other clinical and laboratory parameters were insensitive for the diagnosis of EM. Only 40% of patients had у1 symptom of meningitis, and the results of Gram staining of CSF specimens were positive for only 7 patients (47%). CSF infection was monomicrobial and polymicrobial in 10 and 5 of the patients, respectively. Two of the EM strains were resistant to third-generation cephalosporins before the initiation of antimicrobial therapy. PFGE revealed that each of the Enterobacter aerogenes ( ) and Enterobacter cloacae n p 9 ( ) CSF isolates had a unique genotype. Non-CSF Enteron p 6 bacter isolates were not available for genotype comparison with CSF isolates.
Antimicrobial therapy and outcomes. Patients received antimicrobial therapy directed against Enterobacter species and other CSF isolates (table 3) for a median duration of 14 days. Eight patients (53%) received monotherapy with a carbapemen ( ), a third-generation cephalosporin ( ), piperacillin n p 4 n p 1 ( ), or ciprofloxacin ( ). Seven patients (47%) ren p 1 n p 2 ceived combination antimicrobial therapy, including 6 patients who received an intrathecal aminoglycoside (median duration of therapy, 3 days) with either a carbapenem ( ) or a n p 5 cephalosporin (
) and 1 patient who received a carbapen p 1 nem and a cephalosporin. Overall, carbapenems were administered to 9 patients (60%). No seizures were observed in any of the patients who received meropenem ( ) or imipenem n p 6 ( ) therapy. No in vitro antimicrobial resistance developed n p 3 during therapy among the 13 patients from whom carbapenemand cephalosporin-susceptible Enterobacter isolates were recovered. There was no association between treatment regimen and neurosurgical diagnosis, type of invasive procedure, or severity of illness. However, carbapenems were more commonly administered during the latter half of the study period (1992-1995 vs. 1996-1999, 2 of 6 vs. 7 of 9 patients;
). All 11 patients P p .13 with external CSF drains had the device removed or replaced within 24 h after the diagnosis of EM, and 7 patients underwent additional surgery to treat local wound infections or CSF leakage.
Of the 15 patients, 12 had у1 additional CSF culture performed after the diagnosis of EM (range, 2-15 CSF cultures and 1-8 Enterobacter CSF isolates per patient). Among these 12 patients, the median time to sterilization of the CSF was 2 days. Fourteen patients (93%) with EM were cured. Duration of EM therapy, interval to CSF sterilization, duration of hospitalization, disposition and GCS at discharge, and mortality were similar among patients receiving the different antimicrobial regimens, except for patients who received ciprofloxacin monotherapy. Compared with the other 13 patients with EM, the 2 patients who received intravenous ciprofloxacin monotherapy received significantly longer durations of therapy (median, 39.5 vs. 12 days;
), and there were trends toward P p .04 longer hospitalization (median, 45.5 vs. 17 days;
) and P p .06 time to CSF sterilization (median, 21 vs. 3 days;
). Two P p .11 patients had EM associated with strains that were initially resistant in vitro to third-generation cephalosporins (MIC of ceftizoxime, 116 mg/mL). The first patient with E. aerogenes meningitis died with clinical and microbiological failure after treatment with ceftizoxime, and the second patient with E. cloacae meningitis was treated successfully with imipenem and had sterile CSF cultures after 3 days of therapy. First neurosurgical procedure performed Evacuation or embolization of intracranial blood or fluid 4 (27) Parenchymal resection 4 (27) CSF shunt insertion 3 (20) Spinal surgery 3 (20) Optic nerve decompression 1
Second neurosurgical procedure performed Risk factor analysis. The 13 case patients with EM acquired at the UCLA Medical Center and the 26 controls were similar with respect to demographic characteristics, neurological diagnoses, and types of neurosurgical procedures performed. Severity of illness measurements and clinical parameters were also similar, including median duration of stay in the intensive care unit and initial GCS and ASA scores, except that case patients had higher peripheral WBC counts (median, 13,300 cells/cm 3 vs. 8500 cells/cm 3 ; ) on the referent P p .01 date.
Case patients were significantly more likely than controls to have an external CSF drainage catheter, to have undergone craniotomy, to have developed a postoperative CSF leak, and to have required reoperation within 48 h of the initial procedure (table 4) . Among patients with external CSF drainage catheters, case patients tended to have these devices for a longer duration (median, 14.0 vs. 7.0 days;
). Although the duration of P p .13 previous antimicrobial therapy was similar, controls were more likely than case patients to have received antimicrobial drugs before the referent date that were active in vitro against Enterobacter species (22 of 26 controls vs. 5 of 13 case patients; OR, 0.11; 95% CI, 0.02-0.66;
). Multivariate analysis P p .008 revealed that external CSF drainage catheters, isolation of Enterobacter species from a non-CSF culture, and receipt of previous antimicrobial drugs inactive in vitro against Enterobacter species were independent risk factors for EM (table 4) .
DISCUSSION
Among adults, gram-negative bacillary meningitis is an uncommon infection associated with advanced age, immunosuppression, and neurosurgery [7, [13] [14] [15] . Compared with other risk groups, postneurosurgical gram-negative bacillary meningitis typically occurs among patients without comorbidities and tends to have a more indolent presentation and benign course, despite a higher prevalence of antimicrobial resistance [3, 13, 14, 16] . In our 8-year study, isolation of Enterobacter species from CSF occurred exclusively among neurosurgical patients and infrequently (12% of isolates) was determined to be a CSF contaminant, although we cannot exclude misclas- sification of some cases. Carbapenem-or cephalosporin-based regimens were similarly effective in treating EM in a group of critically ill neurosurgical patients. Although cases of EM were genotypically unrelated, they were more likely to occur during the spring and summer months. Higher rates of isolation of Enterobacter species have been reported in patients who are hospitalized in the United States during the summer months, compared with the winter months [17] . After the introduction of third-generation cephalosporins into clinical practice, dramatic decreases in meningitis-associated mortality were reported [18] [19] [20] . However, the use of these antimicrobial drugs for the treatment of suspected or confirmed nosocomial gram-negative bacillary meningitis is threatened by the emergence of strains with plasmid-encoded or inducible chromosomal b-lactamases that hydrolyze extended-spectrum cephalosporins [21] [22] [23] [24] [25] . These resistance mechanisms have been described in meningitis-associated strains of Enterobacter and were associated with a poor treatment response [6, 7] . In this study, resistance to third-generation cephalosporins was detected in 2 CSF isolates and likely contributed to the death of 1 patient.
Treatment options for the management of cephalosporinresistant EM are limited and include trimethoprim-sulfamethoxazole and carbapenems. Although trimethoprim-sulfamethoxazole has successfully been used for treatment of EM, concern about Pseudomonas aeruginosa and other resistant gramnegative organisms has limited the use of this agent to empirical therapy for gram-negative bacillary meningitis in neurosurgical patients [7, 26, 27] . To our knowledge, this is the largest reported series of neurosurgical patients treated with carbapenems for EM, and the clinical and microbiological responses to therapy were excellent. Compared with cephalosporins and trimethoprim-sulfamethoxazole, carbapenems have a broader spectrum of activity against gram-negative organisms, especially against b-lactamase-producing strains [28] . Although the risk of seizures in neurosurgical patients treated with carbapenems is a concern, meropenem has a low reported risk of seizures (0.05%-0.8%), and the 2%-7% rate reported with imipenemcilastatin can be decreased by appropriate dosage adjustment in patients with renal insufficiency [29, 30] .
The most common risk factors for clusters of nonmeningeal infections due to unrelated strains of Enterobacter include uriDownloaded from https://academic.oup.com/cid/article-abstract/37/2/159/300418 by guest on 31 January 2019 nary or respiratory tract colonization and previous exposure to antimicrobial drugs, especially to broad-spectrum b-lactams [31] [32] [33] . In our investigation, among the 15 clonally unrelated cases of nosocomial EM, we found that Enterobacter colonization or infection at a non-CSF site, selective antimicrobial pressure, and external CSF drainage catheters were independent risk factors. Increasingly, external CSF drainage catheters are used to manage critically ill neurosurgical patients with elevated intracranial pressure [34] [35] [36] . They provide a potential portal of entry for microorganisms and have been associated with a risk of infection of 4%-11% for ventriculostomies and 4.2% for lumbar drains [37] [38] [39] . Reported risk factors for ventriculostomy-associated infection include host factors, such as intracerebral or intraventricular hemorrhage and elevated intracranial pressure, and device factors, including lack of hair removal and sterile occlusive dressings, irrigation of the system, and duration of catheterization of у5 days [37] [38] [39] [40] . In this retrospective analysis, we could not examine potential risk factors related to insertion or maintenance of the external CSF drains. However, during the study period, all CSF drains were inserted by sterile technique, insertion sites were covered with sterile occlusive dressings and were inspected frequently, and sterile technique was used to access the devices.
The role of antimicrobial prophylaxis for patients with external CSF drains remains controversial. Small, uncontrolled studies have yielded conflicting results, and randomized, double-blinded clinical trials are lacking [41, 42] . Two recent retrospective reviews of antimicrobial prophylaxis of CSF drains showed no decrease in the rate of CNS infection and showed an increase in health care costs [43, 44] . Our findings suggest that prolonged antimicrobial administration after insertion of external CSF drains may have the detrimental effect of increasing the risk of EM, especially among patients colonized with Enterobacter species at a non-CSF site.
Although we found that isolation of Enterobacter species at non-CSF sites and receipt of antimicrobial drugs inactive in vitro against Enterobacter species were independent risk factors for EM, our findings do not support the routine administration of broad-spectrum antimicrobial drugs to patients at risk of EM. Rather, all neurosurgical patients with Enterobacter infection at non-CSF sites should receive prompt, appropriate antimicrobial therapy. Those with Enterobacter colonization at non-CSF sites and in external CSF drains or CSF leaks should be carefully monitored for evidence of EM. Because case patients and controls did not routinely have surveillance cultures performed, it is unclear whether receipt of antimicrobial drugs active against Enterobacter species decreased the risk of initial colonization, selective overgrowth, or infection with Enterobacter species at non-CSF sites. Both clinical criteria and CSF surveillance cultures may be used, and both may assist in the prompt recognition of gram-negative bacillary meningitis in this high-risk population [13, 45] .
Our study has several limitations. Although this is the largest reported series of neurosurgical patients with EM to date, the single-institution setting may limit the generalizability of these findings. On the other hand, cases occurred sporadically over an 8-year period and were clonally unrelated. Thus, the risk factors for EM that we identified may be more applicable to other neurosurgical patient populations than to those identified from outbreak investigations. A second limitation is that a higher proportion of case patients, compared with controls, had external CSF drainage devices, suggesting that case patients may have been more severely ill and at greater risk of EM despite having similar GCS and ASA scores.
Although the response of EM to antimicrobial therapy and adjunctive measures was excellent, the optimal approach to management of EM remains incompletely defined. Although all 9 patients treated for EM with carbapenem-based regimens in this series were clinically and microbiologically cured, carbapenem-resistant Enterobacter strains have been reported [46] . Empirical and therapeutic treatment for gram-negative bacillary meningitis requires knowledge of local pathogens and resistance patterns. Prevention of EM and other device-associated infections in neurosurgical patients rests on careful asepsis in critical care and surgical practice, prompt removal of invasive devices, and judicious use of antimicrobial drugs.
